2026年10月16日星期五
M
Всеобъемлющее обозрение
Глобальные новости
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

Global pharma firms walk back innovative drug investments in Japan

Источник 日经 Nikkei Asia3 часов назад
Аннотация

Global pharma firms walk back innovative drug investments in Japan

Сайт предоставляет только заголовки и индексы аннотаций; полный контент и авторские права принадлежат первоисточнику. Для чтения перейдите по ссылке на оригинал.

Перейти к оригиналу
Канал
Финансы
Регион
Япония
Язык оригинала
English
Номер записи
business-839627c8

Comments 0 comments

No comments yet. Be the first.

Global pharma firms walk back innovative drug investments in Japan · Всеобъемлющее обозрение